Progress With Palbociclib in Breast Cancer: Latest Evidence and Clinical Considerations

This review provides an update of the available knowledge on the cell cycle and its regulation, on the alterations in cyclin D-CDK4/6-Rb-E2F axis in breast cancer and their roles in endocrine resistance, on the preclinical activity of CDK4/6 inhibitors in breast cancer, and on the clinical development of palbociclib in breast cancer.

 Ther Adv Med Oncol